Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NT 219

Next Previous
Search
Drug Profile

NT 219

Alternative Names: NT-219

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Purple Biotech; TyrNovo
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Insulin receptor substrate protein inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Solid tumours; Squamous cell cancer
  • Preclinical Malignant melanoma

Most Recent Events

  • 09 Apr 2025 University of Colorado plans a phase I/II trial for Squamous cell carcinoma (Recurrent, Metastatic disease, Second line therapy or greater, Combination therapy) in June 2025 (NCT06919666)
  • 10 Mar 2025 Purple Biotech plans a phase II trial in Squamous cell cancer (Recurrent, Metastatic disease, Combination therapy) in the first half of 2025
  • 05 Mar 2025 Purple Biotech has worldwide patent protection for NT 219

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top